Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at 0 times
- Poor long term growth as Net Sales has grown by an annual rate of -5.57% and Operating profit at -214.92% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at 0 times
- The company has been able to generate a Return on Equity (avg) of 12.73% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of -5.57% and Operating profit at -214.92% over the last 5 years
3
With a fall in Net Profit of NAN%, the company declared Very Negative results in Sep 24
4
Risky - No result in last 6 months
Stock DNA
Pharmaceuticals: Major
CNY 500 Million (Small Cap)
NA (Loss Making)
NA
0.00%
0.86
-14.83%
0.18
Revenue and Profits:
Net Sales:
185 Million
(Quarterly Results - Sep 2024)
Net Profit:
-41 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-64.82%
0%
-64.82%
6 Months
-91.78%
0%
-91.78%
1 Year
-92.79%
0%
-92.79%
2 Years
-95.48%
0%
-95.48%
3 Years
-96.74%
0%
-96.74%
4 Years
-98.22%
0%
-98.22%
5 Years
-98.2%
0%
-98.2%
Hainan Poly Pharm. Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-5.57%
EBIT Growth (5y)
-214.92%
EBIT to Interest (avg)
18.09
Debt to EBITDA (avg)
2.78
Net Debt to Equity (avg)
0.86
Sales to Capital Employed (avg)
0.26
Tax Ratio
12.02%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
10.49%
ROE (avg)
12.73%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.18
EV to EBIT
-5.14
EV to EBITDA
-7.14
EV to Capital Employed
0.56
EV to Sales
4.69
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-10.83%
ROE (Latest)
-14.83%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQ
Sep'24
Jun'24
Change(%)
Net Sales
185.10
127.60
45.06%
Operating Profit (PBDIT) excl Other Income
-47.20
-120.00
60.67%
Interest
10.80
32.00
-66.25%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-41.50
-123.50
66.40%
Operating Profit Margin (Excl OI)
-255.10%
-1,361.50%
110.64%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2024 is 45.06% vs -58.25% in Jun 2024
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2024 is 66.40% vs -285.16% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
1,287.00
1,606.90
-19.91%
Operating Profit (PBDIT) excl Other Income
202.40
409.00
-50.51%
Interest
54.60
41.40
31.88%
Exceptional Items
-12.50
-0.10
-12,400.00%
Consolidate Net Profit
85.90
295.00
-70.88%
Operating Profit Margin (Excl OI)
17.50%
184.50%
-16.70%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is -19.91% vs 7.76% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is -70.88% vs -29.19% in Dec 2022
About Hainan Poly Pharm. Co., Ltd. 
Hainan Poly Pharm. Co., Ltd.
Pharmaceuticals: Major
No Details Available.
Company Coordinates 
No Company Details Available






